The science keeps advancing at Evotec, but the share price tells a different story. The Hamburg-based drug discovery specialist unveiled yet another research collaboration this week, this time with Plectonic Biotech, to develop T-cell engagers aimed at solid tumors. The partnership marries Plectonic’s LOGIBODY technology with Evotec’s in-house BiTco platform for bispecific antibodies — an approach that, if successful, could eventually yield novel immunotherapy options.
Yet the market’s response was telling. Shares briefly ticked higher on the announcement before fading, closing Friday at €3.23, a mere 3.0 percent above the 52-week low of €3.14 touched the same day. The stock now sits roughly 15 percent below its 50-day moving average of €3.78, underscoring just how entrenched the downtrend has become.
A Pipeline Growing Faster Than the P&L
The Plectonic deal is the latest in a string of partnerships Evotec has announced in recent weeks, part of its core business model as a contract research and development organization. Roughly a month ago, the company unveiled an AI-powered research tie-up with Odyssey Therapeutics focused on autoimmune and inflammatory diseases.
But investors have grown increasingly indifferent to such headlines. Since the Odyssey announcement, the stock has shed 6.3 percent. The pattern is consistent: Evotec continues to attract reputable research partners and bolster its pipeline in oncology and autoimmune science, yet the capital markets barely register the progress.
That skepticism has solid grounding in the fundamentals. Just over a week ago, Evotec confirmed its first-half 2026 results alongside the lowered full-year guidance it had already flagged in July. Revenue for the first six months came in at €300.1 million, with second-quarter sales of roughly €143.5 million. The adjusted EBITDA picture was uglier still: minus €42.7 million for the half, including minus €20.8 million in the second quarter alone. Management now projects full-year revenue of €570 million to €610 million at incurred FX, with adjusted EBITDA ranging from minus €70 million to minus €105 million.
Since the company confirmed those figures, the stock has dropped another 3.7 percent.
Should investors sell immediately? Or is it worth buying Evotec?
Boardroom Exit Adds to the Overhang
Compounding the operational concerns was the departure of Camilla Macapili Languille from the supervisory board on August 7, announced around the same time as the Odyssey deal. Evotec offered no explanation for whether the exit was tied to strategic disagreements, leaving investors to fill in the blanks. The shares have lost 7.0 percent since that announcement.
Analyst support has also gone quiet. A buy recommendation with a €10 price target, reaffirmed in August, now looks stale — the stock has fallen 7.7 percent since that call and the target sits more than three times above the current price. Aggregated price-target screens show the average consensus has drifted down to roughly €4.60, though that figure reflects a broader expectation rather than fresh analyst action. Broker surveys cited in media reports point to a “Hold” stance with an average target of $3.00, a sign that institutional enthusiasm has cooled considerably.
Early-Stage Science, Long-Dated Rewards
For the Plectonic collaboration specifically, investors should temper expectations about near-term financial impact. The agreement targets preclinical proof-of-concept data — clinical trials are not yet on the agenda. Under Evotec’s partnership model, meaningful milestone payments or licensing revenues would only materialize years down the road, assuming the preclinical results justify advancing the program.
That timeline mismatch helps explain why the market shrugged. The company’s market capitalization now stands at €581.77 million, and the shares have lost 41 percent since the start of the year — a decline that reflects how harshly investors are judging the operational trajectory.
The next significant catalyst arrives November 5, when Evotec reports third-quarter results. That report will offer the first real test of whether the lowered guidance holds or requires further revision. Until then, the company’s steady stream of research alliances may continue to demonstrate scientific credibility, but they are doing little to shift the fundamental picture — or the stock’s downward path.
Ad
Evotec Stock: Buy or Sell?! New Evotec Analysis from September 5 delivers the answer:
The latest Evotec figures speak for themselves: Urgent action needed for Evotec investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from September 5.
Evotec: Buy or sell? Read more here...
